The combination of lenalidomide and mTOR inhibitors was synergistic against several cancer cell lines in preclinical testing.14,15 We therefore tested the combination of lenalidomide and everolimus in patients with advanced solid malignancies. The gene discussed is MTOR; the disease is cancer.